

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: **Ghazwan Saleem Butrous,**
et al



APPLICATION NO.: **To Be Assigned**

Examiner: **To Be Assigned**

FILING DATE: **Filed Herewith**

Group Art Unit: **To Be Assigned**

TITLE: **TREATMENT OF PULMONARY
HYPERTENSION**

Hon. Commissioner for Patents
Washington, D.C. 20231

Sir:

INFORMATION DISCLOSURE STATEMENT
PURSUANT TO 37 C.F.R. § 1.97 ET SEQ.

Applicant(s) herein make(s) available to the U.S. Patent and Trademark Office a copy of PTO-FB-A820 which lists the references cited by the applicant(s), copies of which are enclosed.

The Examiner is requested to consider carefully the complete text of these references in connection with the examination of the above-identified application in accord with 37 C.F.R. § 1.104(a). It is believed the Examiner will concur with applicant's belief that the subject matter presently claimed is neither anticipated nor rendered obvious by the foregoing references.

It is requested that the references listed on the attached form PTO-FB-A820 be included in the "References Cited" portion of any patent issuing from this application (M.P.E.P. § 1302.12).

A prompt and favorable response is earnestly solicited.

Date: 10/11/2000

Respectfully submitted,

A. Dean Olson
Attorney for Applicant(s)
Reg. No. 31,185

Pfizer Inc.
Patent Department, MS 4159
Eastern Point Road
Groton, Connecticut 06340
(860) 441-4904

Claim 6 (Amended) A method according to claim [1 or] 2 wherein the effective amount is from 1 to 10 mg per day.

Please amend claim 7 as follows:

Claim 7 (Amended) A method according to [any preceding claim] claim 2 wherein the PDE5 inhibitor is administered orally.

Please amend claim 9 as follows:

Claim 9 (Amended) A method according to [any one of claims 1 to 6] claim 2 wherein the PDE5 inhibitor is inhaled.

Please Cancel claims 11-20.


REMARKS

Applicants respectfully request entry of the amendments hereinabove, and an early examination and allowance of the claims.

Please charge any additional fees which may be required, or credit any overpayment, to Deposit Account No. 16-1445. Two copies of this sheet are enclosed.

Respectfully submitted,

Date: 10/11/2000



A. Dean Olson
Reg. No. 31,185
Attorney for Applicant

Pfizer Inc.
Patent Department
Eastern Point Road
Groton, CT 06340
Tel.: (860)441-4904